Skip to content

DBV Technologies DBVT Return on equity

Return on equity at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-88.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-44%+26.2pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-48.9%-498pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-53.6%-22.6pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-27.1%-3.7pp
Alumis Inc. logo
Alumis Inc.ALMS
-64.6%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Calculated from DBV Technologies’s reported figures.

Based on trailing twelve months.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's return on equity?
DBV Technologies (DBVT) reported return on equity of -158.9% in Q1 2026.
How has DBV Technologies's return on equity changed year-over-year?
DBV Technologies's return on equity increased by 19.9% year-over-year, from -198.5% to -158.9%.
What is the long-term trend for DBV Technologies's return on equity?
Over 5 years (2020 to 2025), DBV Technologies's return on equity has grown at a 13.4% compound annual growth rate (CAGR), from -80% to -149.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.